These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 37102330

  • 1. Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries.
    George M, Pérez Martin J, AbdelGhany M, Gkalapi F, Jamet N, Kosse RC, Ruiz García Y, Turriani E, Berlaimont V.
    Hum Vaccin Immunother; 2023 Dec 31; 19(1):2202124. PubMed ID: 37102330
    [Abstract] [Full Text] [Related]

  • 2. Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines.
    Mukherjee P, Akpo EIH, Kuznetsova A, Knuf M, Silfverdal SA, Kosalaraksa P, Mihalyi A.
    Expert Rev Vaccines; 2021 Mar 31; 20(3):319-330. PubMed ID: 33660582
    [Abstract] [Full Text] [Related]

  • 3. Hexavalent vaccines: What can we learn from head-to-head studies?
    Knuf M, Haas H, Garcia-Corbeira P, Turriani E, Mukherjee P, Janssens W, Berlaimont V.
    Vaccine; 2021 Oct 01; 39(41):6025-6036. PubMed ID: 34531081
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety profile of Infanrix hexa - 17 years of GSK's passive post-marketing surveillance.
    Puente Gómez I, Verheust C, Hanssens L, Dolhain J.
    Expert Rev Vaccines; 2020 Aug 03; 19(8):771-779. PubMed ID: 32729745
    [Abstract] [Full Text] [Related]

  • 10. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
    Dolhain J, Janssens W, Sohn WY, Dindore V, Mukherjee P.
    Expert Rev Vaccines; 2019 Sep 03; 18(9):921-933. PubMed ID: 31328999
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK, Rajadurai VS, Amin Z, Sriram B, Yee MF, Han HH, Bock HL, Safary A.
    Southeast Asian J Trop Med Public Health; 2004 Sep 03; 35(3):685-92. PubMed ID: 15689088
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group.
    Pediatr Infect Dis J; 2006 Aug 03; 25(8):713-20. PubMed ID: 16874171
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
    Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P.
    Eur J Pediatr; 2002 Nov 03; 161(11):581-7. PubMed ID: 12424582
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ.
    Vaccine; 2006 May 29; 24(22):4727-36. PubMed ID: 16616973
    [Abstract] [Full Text] [Related]

  • 20. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S.
    BioDrugs; 2010 Oct 01; 24(5):299-302. PubMed ID: 20795752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.